Clinical Trials Browser

Phase 3 × Bortezomib × Dermatologic × Clear all

NCT01386398 2015-01-21

Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

Phase 3 Withdrawn

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous